New vaccine strategy aims to shield spleenless adults from pneumonia
NCT ID NCT02052154
First seen Nov 20, 2025 · Last updated May 11, 2026 · Updated 18 times
Summary
This study tested a two-step vaccine approach to protect adults who have had their spleen removed from serious pneumococcal infections. Participants received one shot of a conjugate vaccine followed by a second shot of a polysaccharide vaccine two months later. The goal was to see if this combination triggers a strong immune response against nine common pneumonia-causing bacteria strains. The study involved 70 adults and followed them for 36 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMIZED PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.